6533b874fe1ef96bd12d6331
RESEARCH PRODUCT
Targeting MYCN in Pediatric and Adult Cancers
Zhihui LiuSaki ClarkeVeronica VeschiCarol J. ThieleSamuel S. Chensubject
Cancer ResearchCancercofactorReviewSynthetic lethalityMYCBiologymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPediatric cancerlcsh:RC254-282pediatric cancerOncologyTranscription (biology)MYCNCancer researchmedicinecancerFunctional studiesSuper-enhancer (SE)Transcription factorPsychological repressionN-Mycneoplasmstranscription factordescription
The deregulation of theMYCfamily of oncogenes, includingc-MYC,MYCNandMYCLoccurs in many types of cancers, and is frequently associated with a poor prognosis. The majority of functional studies have focused onc-MYCdue to its broad expression profile in human cancers. The existence of highly conserved functional domains betweenMYCNandc-MYCsuggests thatMYCNparticipates in similar activities.MYCencodes a basic helix-loop-helix-leucine zipper (bHLH-LZ) transcription factor (TF) whose central oncogenic role in many human cancers makes it a highly desirable therapeutic target. Historically, as a TF, MYC has been regarded as “undruggable”. Thus, recent efforts focus on investigating methods to indirectly target MYC to achieve anti-tumor effects. This review will primarily summarize the recent progress in understanding the function ofMYCN. It will explore efforts at targetingMYCN, including strategies aimed at suppression ofMYCNtranscription, destabilization of MYCN protein, inhibition ofMYCNtranscriptional activity, repression of MYCN targets and utilization ofMYCNoverexpression dependent synthetic lethality.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-02-01 | Frontiers in Oncology |